Effects of Dietary Sodium and Protein Intake on Glomerular Filtration Rate in Subjects with Type 2 Diabetes Treated with Sodium-Glucose Cotransporter 2 Inhibitors

被引:0
|
作者
Gaudio, Costanza [1 ,2 ]
Seghieri, Marta [3 ,4 ]
Merciai, Chiara [1 ]
Colombi, Claudia [3 ]
Spatoliatore, Giuseppe [1 ]
Baggiore, Cristiana Maria [3 ]
Rosati, Alberto [1 ]
机构
[1] Nuovo San Giovanni Dio Hosp, Nephrol Unit, Florence, Italy
[2] Univ Florence, Dept Biomed Expt & Clin Sci Mario Serio, Florence, Italy
[3] Nuovo San Giovanni Dio Hosp, Diabet Unit, Florence, Italy
[4] Nuovo Osped San Giovanni Dio, Via Torregalli 1, I-50143 Florence, Italy
关键词
SGLT2; inhibitors; estimated GFR; creatinine clearance; salt intake; protein intake; KIDNEY; EMPAGLIFLOZIN; DAPAGLIFLOZIN; DECREASE; OUTCOMES;
D O I
10.1055/a-2041-1516
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Approximately one-fourth of patients treated with sodium-glucose cotransporter 2 inhibitors (SGLT2i) experience an acute estimated glomerular filtration rate (eGFR) reduction of more than 10 % ("dippers"). High sodium and protein intake can increase intraglomerular pressure and predispose to a decline in renal function. We investigated whether measured creatinine clearance (CrCl) is a sensitive enough method to detect the initial dip of GFR and if dietary sodium and protein intake might influence the extent of the early change in GFR. Methods 28 subjects with type 2 diabetes (T2D) were enrolled. For sodium and urea determination, 24-h urinary samples were collected to estimate sodium and protein intake respectively before and 1, 3 and 6 months after SGLT2i initiation. Results Mean CrCl was 83.23 +/- 25.52 mL/min/1.73 m(2) (eGFR 67.32 +/- 16.07) and dropped by 19 % at month 1 (eGFR by 6 %). Dippers were 64 and 40 %, according to CrCl and eGFR, respectively. Exploring the potential correlation between changes in renal function and salt intake,.CrCl and baseline urinary sodium were inversely related at month 1 (r = -0,61; p < 0.01), at month 3 (r = -0.51; p = 0.01) and month 6 (r = -0,48; p < 0.05). Likewise, an inverse correlation between.CrCl and baseline urinary urea was demonstrated at months 1 and 3 (r = -0.46; p < 0.05 for both); at month 6, a similar trend was observed (r = -0.47; p = 0.054). Conclusions The present study suggests that a higher dietary sodium and protein intake may amplify the extent of the early dip in GFR, as detected with measured CrCl, in diabetic patients undergoing SGLT2i treatment.
引用
收藏
页码:254 / 259
页数:6
相关论文
共 50 条
  • [21] Safety of sodium-glucose cotransporter 2 inhibitors in Asian type 2 diabetes populations
    Davidson, Jaime A.
    Sukor, Norlela
    Hew, Fen-Lee
    Mohamed, Mafauzy
    Hussein, Zanariah
    JOURNAL OF DIABETES INVESTIGATION, 2023, 14 (02) : 167 - 182
  • [22] Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
    Tang, Jun
    Ye, Lifang
    Yan, Qiqi
    Zhang, Xin
    Wang, Lihong
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [23] Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus
    Carlson, Curt J.
    Santamarina, Marile L.
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (10) : 1401 - 1412
  • [24] Sodium-glucose cotransporter 2 inhibitors as a treatment for heart failure
    Docherty, Kieran F.
    Petrie, Mark C.
    HEART, 2022, 108 (04) : 312 - 320
  • [25] The anti-hypertensive effects of sodium-glucose cotransporter-2 inhibitors
    Kugathasan, Luxcia
    Dubrofsky, Lisa
    Advani, Andrew
    Cherney, David Z. I.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2023, 21 (01) : 15 - 34
  • [26] Performance of sodium-glucose cotransporter 2 inhibitors in cardiovascular disease
    Khater, Jacinthe
    Malakouti, Sara
    El Khoury, Antoine
    Cortese, Bernardo
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2024, 25 (04) : 247 - 258
  • [27] Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review
    Fonseca-Correa, Jorge I.
    Correa-Rotter, Ricardo
    FRONTIERS IN MEDICINE, 2021, 8
  • [28] Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes
    Xie, Yan
    Bowe, Benjamin
    Gibson, Andrew K.
    McGill, Janet B.
    Maddukuri, Geetha
    Al-Aly, Ziyad
    JAMA INTERNAL MEDICINE, 2021, 181 (08) : 1043 - 1053
  • [29] Sodium-Glucose Cotransporter 2 Inhibitors and their Renal benefits in type 2 diabetes. A Systematic Review
    Rehman, Saad Ur
    Rahman, Faiqa
    WORLD FAMILY MEDICINE, 2020, 18 (08): : 57 - 68
  • [30] Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes
    Yoshimoto, Takuo
    Furuki, Takayuki
    Kobori, Hiroyuki
    Miyakawa, Masaaki
    Imachi, Hitomi
    Murao, Koji
    Nishiyama, Akira
    JOURNAL OF INVESTIGATIVE MEDICINE, 2017, 65 (07) : 1057 - 1061